College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 10029, China; Center for Clinical Laboratory,The Affiliated Taian City Central Hospital of Qingdao University, Taian 271000, Shandong, China.
College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 10029, China.
Virus Res. 2022 Oct 2;319:198873. doi: 10.1016/j.virusres.2022.198873. Epub 2022 Jul 19.
Klebsiella pneumoniae, a multidrug resistant bacterium that causes nosocomial infections including septicemia, pneumonia etc. Bacteriophages are potential antimicrobial agents for the treatment of antibiotic resistant bacteria. In this study, a novel bacteriophage IME184, was isolated from hospital sewage against clinical multi-drug resistant Klebsiella pneumoniae. Transmission electron microscopy and genomic characterization exhibited this phage belongs to the Molineuxvirinae genus, Autographiviridae family. Phage IME184 possessed a double-stranded DNA genome composed of 44,598 bp with a GC content of 50.3%. The phage genome encodes 57 open reading frames, out of 26 are hypothetical proteins while 31 had assigned putative functions. No tRNA, virulence related or antibiotic resistance genes were found in phage genome. Comparative genomic analysis showed that phage IME184 has 94% similarity with genomic sequence of Klebsiella phage K1-ULIP33 (MK380014.1). Multiplicity of infection, one step growth curve and host range of phage were also measured. According to findings, Phage IME184 is a promising biological agent that infects Klebsiella pneumoniae and can be used in future phage therapies.
肺炎克雷伯菌是一种多药耐药菌,可引起医院感染,包括败血症、肺炎等。噬菌体是治疗抗生素耐药菌的潜在抗菌药物。在这项研究中,从医院污水中分离到了一种针对临床多药耐药肺炎克雷伯菌的新型噬菌体 IME184。透射电子显微镜和基因组特征表明,该噬菌体属于 Molineuxvirinae 属、Autographiviridae 科。噬菌体 IME184 具有由 44598bp 组成的双链 DNA 基因组,GC 含量为 50.3%。噬菌体基因组编码 57 个开放阅读框,其中 26 个是假定蛋白,31 个具有推定功能。噬菌体基因组中未发现 tRNA、毒力相关或抗生素耐药基因。比较基因组分析表明,噬菌体 IME184 与肺炎克雷伯菌噬菌体 K1-ULIP33(MK380014.1)的基因组序列具有 94%的相似性。噬菌体的感染复数、一步生长曲线和宿主范围也进行了测量。根据研究结果,噬菌体 IME184 是一种有前途的生物制剂,可感染肺炎克雷伯菌,可用于未来的噬菌体治疗。